Latest news:

Follicum’s Clinical Study Shows Stimulation of Hair Growth

Follicum AB hereby announces that the FOL-005 study at the Charité hospital in Berlin, Germany, has shown a stimulation of hair growth in treatment of healthy volunteers. In February 2017, Follicum is able to announce that the company’s phase I/IIa clinical study of the FOL-005 candidate drug showed a good safety profile, and that no […]

Sign up for our Newsletter


Our drug candidates both inhibit and stimulate hair growth, and as they are based on endogenous proteins they are considered safe

Read more


The global market is over 15 billion USD a year and increasing, with few competitors to our drug candidates

Read more


We want to develop safe, effective and cost effective drugs, suitable for both men and women, that have minimal side effects

Read more


05 Apr 17
Annual Report 2016 available

Follicum AB’s Annual Report for 2016 has now been published in Swedish. Annual Report 2016 (in...